Trulicity Complete Drug-Drug Interaction Profile (Dulaglutide)

Trulicity (dulaglutide) is administered as a once-weekly subcutaneous injection and functions as a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. The FDA has approved Trulicity to improve blood glucose levels in type 2 diabetes and to lower the risk of major cardiovascular events in patients with type 2 diabetes who have existing heart disease or multiple risk factors for cardiovascular disease. Trulicity differs structurally from semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound); findings regarding drug interactions with these medications may not apply to Trulicity.

The core clinical picture in one place: dulaglutide's most consequential drug interactions are pharmacodynamic, not pharmacokinetic, because it does not meaningfully affect CYP450 enzymes; the dominant pharmacokinetic mechanism is delayed gastric emptying, which can shift the absorption timing of co-administered oral drugs without changing total exposure for most of them. The two management actions with the clearest evidence behind them are reducing insulin or sulfonylurea doses when starting dulaglutide, and monitoring INR more closely in patients on warfarin during initiation and dose escalation. Precise percentage changes in peak drug concentration reported in older summaries of this topic vary by source and dose, and should be verified against the current FDA-approved prescribing information before being used for patient counseling.

How dulaglutide works, and why that shapes its interaction profile

Dulaglutide activates GLP-1 receptors on pancreatic beta cells, the vagus nerve, and the stomach wall. This triggers glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. Because insulin release is glucose-dependent, dulaglutide alone carries a comparatively low intrinsic hypoglycemia risk. The interaction picture changes when it is combined with drugs that lower glucose independently of the current glucose level, which is the case for insulin and sulfonylureas.

The gastric-emptying effect is the other pillar of dulaglutide's interaction profile. Slower emptying means an oral drug taken around the time of injection may reach the bloodstream more slowly and at a lower peak concentration, even if the total amount absorbed over time is unchanged. This matters most for drugs where a fast peak concentration is part of how they work (short-acting pain relievers) or where a narrow therapeutic window makes any absorption change worth watching (warfarin, digoxin).

Pharmacokinetic effects: what slowed gastric emptying can and cannot do

Dulaglutide is not a substrate, inhibitor, or inducer of major CYP450 enzymes and does not appear to meaningfully affect P-glycoprotein transport. This means classic hepatic-metabolism drug interactions are not expected to be a major concern with dulaglutide. The interactions that do occur are absorption-phase effects tied to gastric emptying.

Acetaminophen and other oral analgesics. The FDA-reviewed pharmacokinetic studies behind the Trulicity label describe reduced peak concentration and delayed time-to-peak for acetaminophen when co-administered with dulaglutide, with total drug exposure (AUC) preserved. In practice, this means a patient using acetaminophen for acute pain may notice a delayed onset of relief, particularly in the first weeks after starting dulaglutide or after a dose increase. The exact percentage change reported in the label should be checked directly rather than quoted from secondary summaries, since figures circulating online for this comparison are inconsistent.

Oral contraceptives. Labeled pharmacokinetic data for ethinylestradiol and norgestimate-type progestins co-administered with dulaglutide do not show a reduction in exposure expected to compromise contraceptive efficacy. As a precaution, the label suggests taking oral contraceptives well before or after the weekly injection if a patient wants to minimize any transient absorption change, though this is described as a precaution rather than a requirement to avoid pregnancy risk.

Warfarin. This deserves separate treatment (see below) because the mechanism is more complex than a simple Cmax shift.

Digoxin, atorvastatin, ACE inhibitors, and similar oral drugs. These drugs have been studied for co-administration with dulaglutide, and the general pattern reported is a shift in time-to-peak concentration with a smaller or negligible change in total exposure. Because digoxin has a narrow therapeutic index and non-linear kinetics, checking a serum digoxin level around the time dulaglutide is started or escalated is a reasonable precaution even though large exposure changes have not been demonstrated. For statins such as atorvastatin, taking the statin in the evening (a common dosing pattern regardless of dulaglutide) largely avoids any same-day timing overlap with a morning injection. Specific percentage changes reported for these drugs vary across sources and should be confirmed against the current label before being treated as fixed numbers.

Pharmacodynamic effects: the interactions that actually change what you prescribe

Insulin. Adding dulaglutide to basal insulin is an approved combination strategy and is supported by trial evidence showing improved glycemic control when the two are combined, along with a higher rate of hypoglycemia compared with insulin alone. Because of this, guideline sources recommend considering a basal insulin dose reduction when starting a GLP-1 receptor agonist in a patient who is already near their glycemic target, to avoid an early run of hypoglycemia. Patients on basal-bolus regimens (with rapid-acting insulin at meals) carry a higher combined risk and benefit from more frequent glucose monitoring for the first several weeks after starting or escalating dulaglutide.

Sulfonylureas (glipizide, glimepiride, glyburide). These drugs stimulate insulin release regardless of glucose level, and that effect stacks with dulaglutide's glucose-dependent insulin release. The prescribing information calls for reducing the sulfonylurea dose when dulaglutide is started. A reduction in the range of one-quarter to one-half of the prior dose is a common starting point in practice, adjusted from there based on glucose logs, but this is a clinical judgment made with the prescriber, not a fixed rule for every patient.

Meglitinides (repaglinide, nateglinide) share the insulin-secretagogue mechanism with a shorter duration of action. The added hypoglycemia risk is concentrated around mealtimes, and skipping a meal while on this combination is a recognized trigger for low blood sugar.

Warfarin: a special case worth its own explanation

Warfarin's effect (measured by INR) depends on both the drug's own absorption and on dietary vitamin K intake, both of which can be affected by changes in gastric motility. Dulaglutide does not inhibit CYP2C9, the enzyme that metabolizes warfarin, so this is not a classic metabolic interaction. Instead, slower gastric emptying can shift the timing and amount of warfarin absorption and of vitamin K absorption from food, and either change can move INR in either direction, particularly in the weeks after dulaglutide is started or the dose is increased.

The practical response described in the label is more frequent INR monitoring around initiation and after each dose escalation, with dose adjustment guided by the INR trend rather than a preemptive fixed change to the warfarin dose. A reasonable monitoring cadence in practice is an INR check within the first one to two weeks after a change, and again a few weeks later, before returning to the patient's usual monitoring interval once values are stable. Case reports describing meaningful INR shifts in patients starting a GLP-1 agonist without adjusting warfarin monitoring exist in the literature, but a specific citation for the magnitude of that shift could not be verified against a primary source for this article and should not be quoted as an exact figure.

Drugs that work against dulaglutide's glucose-lowering effect

Beta-blockers. Non-selective beta-blockers can blunt the tachycardia that normally warns a patient of hypoglycemia. This matters most in patients also taking insulin or a sulfonylurea alongside dulaglutide. Sweating is a hypoglycemia symptom that persists even when the heart-rate response is blunted, and patients on beta-blockers plus a secretagogue should be told to watch for it specifically.

Corticosteroids. Systemic steroids raise blood glucose and work against dulaglutide's effect. Because dulaglutide is a weekly injectable, it cannot be adjusted day to day the way an oral agent or insulin can, so a short steroid course (for example, an asthma flare treated with a several-day prednisone taper) often needs a temporary increase in another antidiabetic agent, most often rapid-acting insulin, as a bridge.

Thiazide diuretics. Thiazides can cause a modest rise in fasting glucose through potassium depletion and other mechanisms. At typical antihypertensive doses this effect is usually small, and a glucose check within a couple of months of starting or increasing a thiazide is a reasonable precaution rather than an urgent one.

Second-generation antipsychotics (notably olanzapine and clozapine). These drugs are associated with weight gain and insulin resistance, both of which can work against the glucose-lowering and weight effects seen with dulaglutide. A patient on dulaglutide who is prescribed one of these medications may need closer follow-up of glycemic targets and, in some cases, dose escalation of dulaglutide within its approved range.

Cardiovascular context: what REWIND actually tells you about interaction safety

The REWIND cardiovascular outcomes trial studied dulaglutide 1.5 mg weekly against placebo, added on top of standard care, in a large population of adults with type 2 diabetes who mostly had multiple cardiovascular risk factors rather than established disease. The trial reported a reduction in major cardiovascular events (a composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death) in the dulaglutide group. This population was heavily co-medicated with statins, ACE inhibitors or ARBs, and aspirin at baseline, which is useful context for interaction questions: the cardiovascular benefit was observed in a real-world polypharmacy setting, not in a drug-free population.

Decision framework: how to think about a specific co-prescription

Use this sequence when a patient on dulaglutide is starting, or already taking, another medication. It is a structure for the conversation with the prescriber or pharmacist, not a substitute for an individualized dosing decision.

Exceptions and edge cases: patients with declining kidney function on dulaglutide plus metformin need attention not because of a dulaglutide-metformin interaction (there isn't one) but because metformin itself becomes contraindicated at low eGFR, which can force a change in the whole regimen. Patients over 65 are more likely to be on several of the drugs above at once, so a full medication reconciliation before the first dulaglutide prescription is more useful than checking interactions one at a time.

What is established, what is plausible, and what is not established

Established: dulaglutide slows gastric emptying and does not meaningfully affect CYP450 metabolism; combining it with insulin or a sulfonylurea increases hypoglycemia risk and is managed by reducing the other drug's dose; warfarin patients need closer INR monitoring around initiation and dose changes.

Plausible but not firmly quantified in the material available for this article: the exact percentage changes in peak concentration and time-to-peak for specific co-administered oral drugs (acetaminophen, atorvastatin, lisinopril, digoxin). Directionally these effects are real and described in the FDA label, but precise figures should be pulled from the current label text rather than repeated from secondary sources, which vary.

Not established from the sources available here: a quantified rate of INR shift caused specifically by dulaglutide initiation, and a head-to-head ranking of interaction severity across all GLP-1 receptor agonists. Comparative claims about dulaglutide versus semaglutide or other agents on interaction risk should be treated as unverified until checked against a primary comparative pharmacokinetic study.

When to seek urgent care

Confusion, slurred speech, seizure, or loss of consciousness in a patient on dulaglutide plus insulin or a sulfonylurea is a medical emergency and should prompt immediate glucose treatment and emergency care if the person cannot safely swallow or is not improving quickly. Unexplained bruising or bleeding in a patient on dulaglutide and warfarin warrants an urgent INR check rather than waiting for the next scheduled draw.